Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release


Posted on: 12 Sep 17

Combines ANGLE’s CTC harvesting technology with QIAGEN’s downstream analysis and bioinformatics capabilities for circulating tumor cell research  


ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce it has established a co-marketing agreement with QIAGEN, a world-leading provider of molecular testing solutions with more than 500,000 customers in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research).  


The partnership will seek to leverage the advantages of combining ANGLE’s world leading Parsortix system for harvesting circulating tumor cells (CTCs) with QIAGEN’s liquid biopsy solution portfolio which consists of dedicated NGS (next generation sequencing), PCR (polymerase chain reaction), single cell analysis products and bioinformatics capabilities.  The initial focus will be on prostate and breast cancer research applications. 


The agreement entails both companies offering the other’s products to its customer base and follows an intensive evaluation of Parsortix by QIAGEN identifying the advantages of the system.


Michael Kazinski, QIAGEN’s Senior Director Molecular Preanalytic Technologies commented:

“ANGLE’s Parsortix system is a unique, epitope-independent CTC solution offering easy, automated processing of whole blood to harvest all types of CTCs, including the clinically relevant mesenchymal CTCs, for analysis.  It complements very well with our AdnaTest CTC portfolio, now allowing for both phenotypic and molecular characterization of CTCs. The modular combination abilities of this system with QIAGEN’s liquid biopsy-based Sample to Insight offering, including AdnaTest, our targeted RNAseq and single cell solutions, along with our bioinformatics offering, will allow scientists and clinical researchers to significantly advance their research.”


ANGLE Founder and Chief Executive, Andrew Newland, commented:

“We are delighted that Parsortix has been selected by QIAGEN as their label-free CTC harvesting technology. We believe the ability to offer customers a combination of Parsortix with validated and reliable downstream analysis technologies from a world leader such as QIAGEN facilitates key aspects of the sales cycle and we look forward to working closely together. Partnering is a core part of ANGLE’s strategy to secure widespread adoption of Parsortix right across the market leveraging the customer base and distribution channels of established players.”


QIAGEN is a world-leading provider of liquid biopsy solutions for molecular testing from Sample to Insight. In 2015, QIAGEN introduced the first regulated companion diagnostic assay based on molecular biomarkers from circulating tumor DNA. QIAGEN has created a wide range of strong standards for the processing of liquid biopsy samples, including circulating cell free DNA, messenger RNA, circulating tumor cells, exosomes and others. Many of the solutions offer fully integrated and highly automated workflows spanning from collection through to the purified nucleic acid. The QIAGEN solutions are used in numerous diagnostic and research workflows and represent gold standards in terms of performance. Such solutions allow liquid biopsies to be easier and less expensive to perform than tissue biopsies and they allow for significantly improved sensitivity, specificity and robustness of liquid biopsies which can be reliably repeated at regular intervals for monitoring of disease progression.



For further information ANGLE:



+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director



finnCap Ltd (NOMAD and Joint Broker)

Corporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne

Corporate Broking - Alice Lane, Nikita Jain


+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes

Nigel Birks



+44 (0) 203 705 9318

+44 (0) 203 705 9316

FTI Consulting

Simon Conway, Mo Noonan, Stephanie Cuthbert

Kimberly Ha (US) 


+44 (0) 203 727 1000

+1 212 850 5612



For Frequently Used Terms, please see the Company’s website on

Editor's Details

Mike Wood

Last updated on: 12/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.